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Cell-division cycle protein 20 homologue (Cdc20) has important functions in chromosome segregation and mitotic exit. 
Cdc20 is the target of the spindle assembly checkpoint (SAC) and a key cofactor of the anaphase-promoting complex or 
cyclosome (APC/C) E3 ubiquitin ligase, thus regulating APC/C ubiquitin activity on specific substrates for their 
subsequent degradation by the proteasome. Here we discuss the roles of Cdc20 in SAC signalling and mitotic exit, 
describe how the integration of traditional approaches with emerging technologies has revealed new details of Cdc20 
functions, comment about the potential of Cdc20 as a therapeutic target for the treatment of human malignancies, and 
discuss recent advances and controversies in the mechanistic understanding of the control of chromosome segregation 
during cell division.  
 
Cdc20 Roles in Mitosis 
The SAC (see Glossary) is an intricate signalling system that prolongs mitosis until all chromosomes achieve correct bipolar 
attachments to spindle microtubules. A proper SAC response involves communication with the kinetochore,  a multiprotein 
structure that constitutes the site for attachment of chromosomes to the microtubule polymers that pull sister chromatids 
apart in dividing cells [1,2]. Defects in chromosome segregation can lead to aneuploidy, a prevalent characteristic of human 
cancer cells, and genome instability [3–5]. Here we describe the importance of Cdc20 in the SAC, the overall structural 
organisation of Cdc20, how multiple protein motifs in this protein act in a concerted fashion to ensure the regulation of 
mitosis progression and mitotic exit, the physiological implications of abnormal Cdc20 expression in humans, and the 
potential of this APC/C regulator as a drug target for innovative anticancer therapies. In humans the SAC is orchestrated by 
the serine–threonine kinases budding uninhibited by benzimidazoles 1 (Bub1), Bub-related1 (BubR1), monopolar spindle1 
(Mps1), and Aurora B and the proteins mitotic arrest deficient-like 1 (Mad1), mitotic arrest deficient-like 2 (Mad2), Bub- 
related 3(Bub3), andBub3-interacting GLEBS-motif-containing ZNF207 (BuGZ). Cell-division cycle protein 20 homologue 
(Cdc20) is a modulator of the ubiquitin E3 ligase APC/C (see Figure IA in Box 1) the cellular activity that drives mitotic exit 
and as discussed below, a bona fide component of the SAC. The SAC inhibits this activity in response to chromosome 
misorientation and/or misattachment to spindle microtubules. SAC proteins are recruited to the kinetochore, inducing 
conformational changes in Mad2 that promote its binding to Cdc20 and BubR1 (known as Mad3 in yeast and worms) to 
form the mitotic checkpoint complex (MCC), a potent inhibitor of the APC/C (see Figure IB in Box 1) [6]. Activation of the 
APC/C requires the binding of its cofactor Cdc20. Once all sister kinetochores are properly attached and bioriented, the SAC 
is satisfied and the chromosomes congress to the metaphase plate, which in turn leads to disassembly of the MCC and the 
release of APC/C inhibition. In the latter process, the Cdc20–APC/C interaction is greatly enhanced by phosphorylation of 
core protein subunits of the APC/C by cyclin-dependent kinases (Cdks). Phosphorylated APC/C can activate and recruit its 
substrates cyclin B and securin for polyubiquitination and their eventual destruction by the proteasome. Molecular 
recognition of cyclin B and securin by the APC/C is mediated by a short protein motif termed the destruction box (D-box) 
comprising the consensus sequence RxxLxxxxN [7]. Degradation of cyclin B results in cyclin B–Cdk1 inactivation and the 
subsequent onset of cytokinesis [8–10]. Therefore, Cdc20 is a protein with a pivotal role in the regulation of chromosome 
segregation and mitotic exit. As discussed below, the dual, antagonistic functions of Cdc20 in the SAC and as an APC/C 
cofactor place this protein at the crossroads of key signalling events that control cell division in eukaryotic organisms.  
2 
 
Multiple Motif Organisation of Cdc20  
Specific motifs found throughout the Cdc20 polypeptide chain are responsible for the interaction of this protein with SAC 
central components and APC/C subunits during the critical transition from metaphase to anaphase. Cdh1, the second 
activator and regulator of substrate specificity of the APC/C [11], shares a similar domain organisation with Cdc20 (see 
Figure IC in Box 1). Cdh1 can bind to securin during the G1 stage of the cell cycle, where the Cdc20 protein levels are low. 
Despite sharing similar domain organisations, the ways in which Cdc20 and Cdh1 interact with the same substrate differ 
[12]. This elicits the question: how exactly do the multiple motifs of Cdc20 dictate its specific yet versatile functions in 
mitosis? A good starting point is to describe Cdc20 as a protein that is organised in two main segments: an N-terminal 
region of low structural complexity and a C-terminal region that defines the WD40 fold. The N-terminal disordered region 
contains C-box, KEN-box, and CRY-box motifs whereas a C-terminal tail after the WD40 domain contains the Ile-Arg (IR) 
motif (Figure 1). The KEN-box and the CRY-box act as two degradation signals (degrons) that function independently from 
each other. The KEN- and the D-box are key APC/C recognition binding sites [13–15]. The KEN-box motif (KENXXXN/D) is 
defined by the amino acid residues lysine (K), glutamate (E), and asparagine (N) (residues 26–28 in human Cdc20). Both the 
KEN- and the CRY-box motif function as APC/C– Cdh1-dependent degrons at the end of mitosis. The Cdc20 CRY-box 
includes the residue S170, which is phosphorylated by polo-like kinase-1 (Plk1), a protein also implicated in the regulation 
of diverse kinetochore and centrosome proteins. Phosphorylation of S170 by Plk1 is critical for the timely ubiquitination 
and destruction of Cdc20 [16]. Despite the fact the KEN- and CRY-box motifs are regulated by APC/C–Cdh1, at least in 
embryos and oocytes the Cdc20 degradation rate mediated by recognition of the CRY-box motif is greater than that 
involving the KEN-box motif [16]. The crystal structure of a truncated form of Cdc20 lacking the flexible N-terminal region 
(PDB 4GGC) revealed a segment organised as a canonical WD40-repeat fold. This protein repeat plays critical roles in Cdc20 
and Cdh1 through the physical interaction of the WD40 repeat with APC/C substrates [12, 17–20]. Each WD40 repeat 
comprises four β strands that define a seven-bladed b-propeller architecture [21]. Each blade is a β sheet of four 
antiparallel strands, with strand order βA, βB, βC, βD, arranged around a central axis with pseudo sevenfold rotational 
symmetry (Figure 2A). The βD strand of one blade intersects to define the strands βA to βC of the next blade. The βD 
strand from the first repeat is the outside strand for the last blade, thus creating a closed structure. In a canonical WD 
motif, the Trp of this signature establishes a pattern of hydrogen bonds in a triad involving residues Ser/Thr, His, and Asp 
[22]. However, the canonical WD signature sequence is largely absent in human Cdc20, with blades one to seven 
terminating in the amino acid pairs WS, WD, HD, WP, WN, WK, and WR, respectively. The sequence divergence affects core 
contacts between blades. Cdc20 proteins from other species also deviate at key residues of the WD40 canonical signature. 
In human Cdc20 the only conserved element of the prototypic triad is the Asp/Asn-Gln sequence at the tip of one of the 
loops. The typical Trp, Ser, and His signature residues are only found in blade six and are conserved in all Cdc20 
homologues (the exception being Cdc20 from zebrafish, in which these residues are substituted by Phe, Ala, and Asn, 
respectively). The top surface and the bottom face of the WD40 domain contain large loops. The blades surround a central 
channel that narrows marginally near the top face. In human Cdc20 the width from the top to the bottom face is ca 27 Å; 
the diameter is ca 48 Å. The crystal structure of Cdc20 in complex with a BubR1 KEN-box motif-mimic peptide (PDB 4GGD) 
provided the first atomic insights on the mode of interaction of Cdc20 with this multidomain SAC pseudokinase and protein 
component of the MCC. The crystallographic structure showed that in Cdc20 the KEN-box- and D-box-binding regions are 
mapped onto the top face of the seven-bladed b propeller in which the KEN-box motif adopts an irregular 310-helix 
architecture. The interaction involves amino acid residues of the loop region that link the first and seventh blades of the 
Cdc20 propeller (residues 183–188 in human Cdc20), which also establish multiple contacts with neighbouring amino acid 
residues to render a shallow top surface. The Cdc20 183–188 region includes a triad defined by residues D184Y185Y186 
that configures a KEN-box motif-binding site. The triad residues physically interact with the side chains of the KEN-box 
motif residues E27 and N28 of BubR1 giving place to an autoinhibited conformation, thus providing molecular details of 
Cdc20 molecular recognition and regulation by BubR1. 
The C-terminal region of Cdc20 contains a conserved IR motif that is essential for Cdc20 recruitment to the APC/C [20, 23, 
24]. Various mechanistic models of the role of the Cdc20 IR motif in the SAC have been proposed. One model postulates 
that Cdc20 binds to the APC/C Apc8/Cdc23 subunit where the SAC is unsatisfied, leaving the TRP motif of the APC/C Apc3 
subunit available for the Cdc20-independent recognition of substrates such as Nek2A [13, 25]. When the SAC is satisfied, 
the IR motifs of Cdc20 and Apc10 bind to one of the two subunits of the Apc3 homodimer thus establishing a stable 
interaction with the APC/C [13, 26–28]. Interestingly, a truncated version of the APC/C regulator Cdh1 lacking the IR tail 
can still bind weakly to the APC/C through the C-box motif located in Cdh1 N-terminal region [24] suggesting that other 
Cdh1 regions are implicated in the productive interaction of Cdh1 with APC/C. 
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Multiple Contacts Mediate the Cdc20–MCC Interaction 
Multiple phosphorylation sites exist in the Cdc20 N-terminal region, a feature that resembles APC/C regulation by 
concerted phosphorylation and dephosphorylation events [29]. Substitution of R132 for alanine impairs Cdc20 binding to 
human Mad2 [30] whereas mutation of residues S41, S42, S72, S92, S153, T157, and S161 for alanine result in reduced 
checkpoint arrest in mitosis, presumably due to the loss of Bub1-mediated phosphorylation [31]. Similarly, suppression of 
Bub1 protein production or expression of a Bub1 dead kinase both abolish Cdc20 phosphorylation and impair the SAC [31], 
confirming the importance of Cdc20 phosphorylation in the SAC. Furthermore, in addition to the aforementioned 
mechanisms of chromosome segregation regulation, an effective SAC response implicates a Cdc20–Bub1–Plk1 axis, as 
concluded from studies conducted in human cells expressing truncated and phosphomimicking Cdc20 mutants [32]. These 
studies showed that the non-catalytic domain of Bub1 can bind to Cdc20 and Plk1 and provides a structural framework for 
the phosphorylation of Cdc20 by the latter kinase [32]. This process, which seems to be required for the in vitro inhibition 
of APC/C–Cdc20 but appeared dispensable for the assembly of the MCC, defined an additional layer of regulation of the 
SAC. 
A further interaction that is essential to elicit a proper SAC response is that of Cdc20 with BubR1. The interaction involves 
two Cdc20-binding regions in the latter protein: one N-terminal KEN-box motif and a short region defined by residues 490–
560 in human BubR1. Different authors refer to this second Cdc20-binding site as the C20BD region [33], the ABBA motif 
(an acronym that alludes to the motif in cyclin A, Bub1, BubR1, and Acm1 proteins) [34], or the Phe box (from the two 
phenylalanine residues that define it; FSIFDE in human BubR1) [35]. The latter report also described a putative C-terminal 
D-box that is important for BubR1 binding to Cdc20 [35]. Similarly, the interaction of Cdc20 with Mad2 is critical for the 
SAC. Mad2 is a 23.5-kDa protein that contains a Hop1p, Rev7p, and MAD2 (HORMA) domain of multiple conformational 
states, including an open (o-Mad2) and a closed (c-Mad2) conformation [36,37]. In the latter conformational state, Mad2 
binds to Cdc20 and to its upstream regulator Mad1. The Cdc20–Mad2 interaction involves a Cdc20-binding region known 
as the Mad2-interacting motif (MIM) [38, 39]. The interaction induces a seatbelt-like structure in C-terminal Mad2 [38, 39]. 
The o-Mad2 conformation results in steric hindrance of the ligand-binding site caused by its C-terminal region, thus 
impeding the adoption of a seatbelt topology and, consequently, the binding of Mad2 to Mad1 or Cdc20 [38]. When the 
SAC is unsatisfied, the Mad1–Mad2 heterocomplex is recruited to unattached kinetochores, which in turn promotes the 
conformational transition of Mad2 from the open to the close state. The association of c-Mad2–Cdc20 with BubR1 and 
Bub3 forms the MCC (Figure 2B) [40]. Comparison of the structure of Cdc20 alone with that of the Cdc20 implicated in the 
MCC from fission yeast (PDB 4AEZ) revealed little conformational change on Cdc20 association with Mad2 and Mad3 (the 
yeast orthologue of BubR1). The only significant difference is a disordered-to-ordered transition of the Cdc20 MIM motif 
on ligand binding [41]. The mode of interaction between human Cdc20 and a surrogate peptide of BubR1 
KEN-box motif was very similar to that observed between Cdc20 and Mad3 in the fission yeast MCC [41], indicating a mode 
of molecular recognition of the BUB kinases by Cdc20 that is evolutionarily conserved. Taken together, these structural 
features reveal Cdc20 as a small, multisubstrate protein that acts as an organiser centre in the regulation of the cell cycle 
and APC/C activity. In addition, the requirement for Cdc20 by the Bub1–Plk1 interaction, the conformational transition of 
Mad2, and the interaction with Mad2 and BubR1 to assemble the MCC, confirm Cdc20 as a bona fide component of the 
SAC. Multiple studies show that the subcellular localisation and functions of Cdc20 are tightly regulated through allosteric 
mechanisms implicating protein–protein interactions, concerted phosphorylation and dephosphorylation cascades, and 
other post-translational modifications including ubiquitination, thus situating Cdc20 at the crossroads of signalling events 
that ultimately ensure genome stability. The implications of Cdc20 as a cell signalling regulatory node that ensures the 
unidirectional flow of information during cell division are discussed below. 
Cdc20 and the Regulation of the APC/C 
The MCC exists both in a free state and stably bound to the APC/C [29, 42, 43]. The MCC binds and inhibits Cdc20-bound 
APC/C (APC/C–Cdc20), forming a large complex called APC/C–Cdc20–MCC that contains two copies of Cdc20. More than 50 
sites are phosphorylated in the APC/C complex during mitosis [44–46]. Under such conditions, phosphorylation of APC/C by 
the Cdk1 kinase controls Cdc20 loading onto APC/C to form an APC/C–Cdc20 complex [42]. Further control of APC/C–Cdc20 
activity in response to the status of the mitotic spindle involves fine-tuned cycles of Cdc20 synthesis and degradation with 
the dynamic association of the MCC and APC/C–Cdc20–MCC assemblies [1, 47, 48]. Two independent breakthrough studies 
reporting high-resolution (i.e., 6.1–4.2-Å resolution) cryoelectron microscopy (cryo-EM) images of APC/C–MCC complexes 
have revealed new clues about APC/C regulation with an unprecedented level of detail [49, 50]. The studies showed that 
the MCC interacts with an APC/C region located in close proximity to the region where a Cdc20 subunit was previously 
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docked (Figure 2C). The multidomain protein BubR1 acts as a pseudosubstrate inhibitor and extends around the two Cdc20 
subunits in such a way that it occupies all degron-binding sites on both copies. In this manner recruitment of the MCC to 
APC/C–Cdc20 physically impedes the recruitment of APC/C substrates (see Figure IB in Box 1) resulting in the allosteric 
regulation of APC/C ubiquitin E3 ligase activity. A large conformational transition leads to an active, open state in which the 
Cdc20 ubiquitination sites Lys485 and Lys490 become accessible to the priming E2 subunit UBE2C of APC/C complex thus 
contributing to the regulation of APC/C–Cdc20–MCC functions. Although the presence of Bub3, a protein involved in 
termination of the SAC [51, 52], was confirmed in a biochemically reconstituted Cdc20–MCC assembly it could not be 
located in the electrondensity maps, suggesting that Bub3 associates with APC/C–Cdc20–MCC in such a way that it remains 
largely flexible on binding the assembly. Ultimately, the conformational dynamics of the interactions confer distinctive 
ubiquitination activities on the APC/C that enable exquisite regulation of mitosis. The overall similarity of EM maps of 
APC/C–Cdc20–MCC complexes with and without Bub3 raises the following questions. Is the association of SAC proteins to 
form the MCC and other subcomplexes sufficient to promote UBE2C-dependent ubiquitination of Cdc20? How exactly are 
the APC/C–Cdc20–MCC open and closed conformations switched in the cell? How exactly does Bub3 associate with APC/C–
Cdc20–MCC to regulate SAC signalling? These are key aspects of cell division regulation that remain to be fully understood. 
Phosphorylation of Cdc20 impairs the ability of the APC/C to activate the chain-forming E2 subunit Ube2S [53]. The 
inhibitory phosphorylation on Cdc20 is released by PP2A-B56, a phosphatase that is recruited to kinetochores by BubR1. In 
addition, depletion of Knl1, the kinetochore anchor of BubR1, prevents PP2A-B56 and UBE2S binding to Cdc20. These 
findings suggest that Cdc20 coordinates the formation of a kinetochore-bound complex that contains BubR1, UBE2S, and 
PP2A-B56 in a phosphoregulated process. In fission yeast PP1 activity is required to reactivate PP2A-B55 and PP2A-B56, 
indicating that at least in this exit [54]. The picture emerging from the studies described above is one of finely controlled 
assembly and disassembly of APC/C–Cdc20 and the MCC that in turn enables allosteric regulation of APC/C activity. This is 
achieved through multiple, cooperative interactions that act in a concerted fashion to ensure tight regulation of 
chromosome segregation and cell cycle progression. In this manner the interactions that control APC/C ubiquitin E3 ligase 
activity can turn the catalytic subunit into a molecular switch that, depending on the precise requirements by the cell at 
that point in time, functions as an inhibitor or a substrate of APC/C–Cdc20. The evolutionary advantage that this intricate 
mode of regulation confers on eukaryotic organisms is evidenced by the severe adverse consequences of APC/C 
deregulation on genome stability, an aspect that is discussed below. 
Cdc20 in Disease 
Abnormal Cdc20 expression appears in a majority of human cancers, including oral squamous cell carcinoma [55], human 
bladder carcinoma [56], and pancreatic [57], colorectal [58], breast [59], brain [60], and lung cell cancer [61], supporting an 
oncogenic role for Cdc20 in promoting tumorigenesis. Suppression of Cdc20 expression in lung cancer and hepatocellular 
carcinoma decreased cell proliferation and induced G2/M cell cycle arrest, and in the latter case positively correlates with 
TNM stage [61, 62]. Due to its association with clinical stage, Cdc20 has been proposed as prognostic biomarker in human 
non-small cell lung cancer (NSCLC) and colorectal cancer [61]. Cdc20 overexpression and poor cell differentiation also occur 
in human pancreatic cancer cells [63]. Depletion of Cdc20 enhanced cell cytotoxicity following treatment with paclitaxel 
and increased the sensitisation of pancreatic cancer cells to gamma irradiation [63], suggesting that Cdc20 could be a 
useful marker to monitor cancer progression and a potential therapeutic target for the treatment of this devastating 
disease. 
A growing number of viruses have been shown to target the APC/C, including human cytomegalovirus (HCMV), human 
papillomavirus (HPV) E2, Orf virus (ORFV), and human T cell lymphotropic virus type 1 (HTLV-1) Tax [64]. The molecular 
strategies deployed by these viruses to infect human cells vary widely. Nevertheless, the manipulation of the APC/C by the 
viruses has the common feature of allowing them to sustain their replication [64]. Although the use of viral particles as 
novel tools to study the APC/C is in its infancy, they may be instrumental in enhancing our understanding of cell division in 
human cells and exploring the possibility of separating the functions of Cdc20 in the assembly of the MCC, regulation of 
APC/C activity, and the exit from mitosis. Towards this aim, it would be of great significance to clarify exactly how viral 
factors affect the activity of the APC/C and to identify all of the APC/C subunits and APC/C–Cdc20 regulators that they 
target. It would also be relevant to assess the global effect of the viruses on cellular metabolism in normal cells and tissue-
specific tumours and define whether APC/C manipulation by viral factors can sensitise cancer cells to drugs and/or gamma 
irradiation and proton beam therapy. It would be equally important to assess the potential benefits of using viral factors 
for cancer therapy and establish their potential use as novel drug-delivery systems targeting the SAC–kinetochore–
microtubule axis more effectively. 
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The Potential of Cdc20 as a Drug Target 
Earlier observations showed that the weakening of SAC core proteins inhibited tumour cell growth, suggesting the SAC 
signalling pathway as a promising pool of new anticancer targets (reviewed in [65]). Such findings stimulated the search for 
and development of inhibitors that target the catalytic site of the SAC kinases Aurora B and Mps1, some of which have 
entered clinical trials. Examples are: the Aurora kinase inhibitor AT9283, which is prescribed for the treatment of non-
Hodgkin's lymphoma (Phase I completed; NCT00443976); the inhibitor PF-03814735, which is used for the treatment of 
histologically or cytologically confirmed malignancies (Phase I completed; NCT00424632); and the Mps1 inhibitor 
BAY1161909 (in Phase I trial for the treatment of solid tumours; NCT02138812) [66, 67]. Unfortunately, the use of small-
sized inhibitors that act as ATP-binding competitors, including those that target SAC kinases, has been of limited success. 
The lack of specificity of these molecules for the intended kinase target, which may result in significant side effects and 
rapid development of drug resistance in treated cells, remain major concerns [68]. Alternative approaches include 
microtubule inhibitors such as vinca alkaloids and taxanes, which have been used to treat breast, ovarian, and lung cancer 
[69]. However, the clinical efficacy of these compounds is limited because of the variable response to microtubule 
inhibitors by the treated cells [70, 71]. The fact that Cdc20 knockdown can lead to SAC-independent mitotic arrest that is 
comparatively more effective in killing cancer cells together with the emerging description of APC/C regulation to a 
unprecedented level of detail should open up new opportunities for exploration of the therapeutic potential of Cdc20 as a 
drug target affecting mitotic exit in cancer cells. In principle, the targeting of specific Cdc20 protein–protein interfaces 
(PPIs) may be a better anticancer therapeutic strategy than perturbing the spindle assembly with spindle-perturbing drugs 
or the use of ATP analogues that bind to kinase domains. This is because the structural and physicochemical features of 
PPIs are far more diverse than those defining the catalytic and/or substrate-binding sites. Ideally, the disruption of a 
specific PPI must have little (if any) effect on other specific interactions mediated by the target protein, thus decreasing the 
risk of undesired side effects. For instance, targeting the Cdc20–BubR1 and/or Cdc20–Mad2 interfaces may allow fine-
tuning of the regulation of free and MCC bound Cdc20 protein levels, which may be effective in harnessing slippage in 
response to mitotic arrest or death in mitotic cells [72]. 
An excellent review discussing the potential of Cdc20 inhibition for the treatment of human malignancies listed 12 bona 
fide protein substrates of APC/C–Cdc20 and 13 substrates of APC/C bound to either the Cdc20 or the Cdh1 cofactor [73]. 
The wide scope of substrate molecules regulated by APC/C–Cdc20 confirms the prominence of APC/C as a master regulator 
of the eukaryotic cell cycle and the opportunity this represents for the treatment of human malignancies. Several small-
sized compounds belonging to various chemical families (Figure 3) have been reported to inhibit APC/C functions. Their 
mode of action is summarised in Table 1 and discussed below. TAME is a mimetic drug of the IR motif involved in Cdc20 
recruitment to the APC/C. TAME functions as a Cdc20 (and Cdh1) competitor of the Cdc20–APC/C interaction leading to 
inhibition of degradation of APC/C substrates [74]. Because TAME is not cell permeable, a prodrug called proTAME, which 
can be processed by in vivo by esterases to yield TAME inside the cell, has been developed. proTAME functions as an 
APC/C–Cdc20 inhibitor to retard tumour cell growth and induces mitotic arrest in the absence of spindle damage in a SAC-
dependent manner. NAHA is a hydroxamic acid derivative that downregulates Cdc20 expression in breast cancer cells 
causing inhibition of cell proliferation and colony formation and reducing tumour weight in vivo [75]. However, the 
underlying molecular mechanism of action of this compound remains largely obscure [76]. GDMT is an alcohol found in a 
certain class of mushrooms that suppresses Cdc20 expression, hence inhibiting the growth and proliferation of aggressive 
breast tumours [77]. Apcin is a small-sized compound that prevents substrate recognition by Cdc20 leading to inhibition of 
ubiquitination of Cdc20 substrates [74]. Apcin binds to the pocket defining the D-box, thus blocking substrate-induced 
Cdc20 loading onto the APC/C [74]. Furthermore, apcin and a few apcin synthetic derivatives synergise with proTAME to 
inhibit mitotic exit in human colorectal and osteosarcoma cancer cells [74, 78]. Withaferin A stimulates Cdc20 and Mad2 
degradation thus interfering with SAC function and extending mitosis. Ganodermanontriol (GDNT) downregulates Cdc20 
expression and acts as an inhibitor of cell proliferation in breast cancer cells [77]. Moreover, a medicinal blend from 
mushrooms, Myco-Phyto® Complex, reportedly acts as a suppressor of the expression of cell cycle regulatory genes 
including  Cdc20, thus inhibiting cell proliferation and invasiveness in breast tumours [79,80]. Regulation of Cdc20 
expression by genistein seems possible in breast cancer cells [81]. CFM-4 is a compound that inhibits cell growth and 
invasion in malignant pleural mesothelioma [82]. In breast cancer cells, CFM-4-induced apoptosis may contribute to 
downregulation of Cdc20 [83].  More recently, the compound 6-brominated coumarin hydrazide–hydrazone derivative 
(BCHHD)-7c was reported to act as an inhibitor of Cdc20 expression in pancreatic cancer cells that were resistant to 
chemotherapy, suggesting that BCHHD-7c could be an effective antitumour drug for the treatment of pharmacologically 
induced drug-resistant cancer cells [84]. However, the precise effect of BCHHD-7c in cells overexpressing Cdc20 and the 
assessment of its potential therapeutic benefits for the treatment of cancer require additional in-depth investigations. 
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None of the naturally occurring inhibitors reported to date (withaferin, GDNT, and genistein) are genuinely specific to 
Cdc20, so further studies are required to develop the molecules into truly specific Cdc20 inhibitors. By contrast, the 
synthetic compound apcin appears to be a specific Cdc20 inhibitor with a direct effect on APC/C–Cdc20 function. Due to 
the fact the inhibition of APC/C activation by apcin and TAME implicate distinct mechanisms, the combinatorial use of 
apcin and TAME can lead to a synergistic effect in human cancer cell lines [74]. Hence, the disruption of specific PPIs by 
simultaneously combining two or more drugs represents a promising new strategy for the treatment of cancer. Recent in 
vitro studies in Cdc20 knockdowns reported inhibition of the growth of human pancreatic carcinoma cells after the delivery 
of liposome-encapsulated Cdc20 siRNA [85]. These results suggest that siRNA methods can be an effective therapeutic 
strategy for the inhibition of tumour growth [85]. It can be anticipated that there will be a surge in the use of siRNA-based 
strategies targeting APC/C subunits, cofactors, and regulators – alone and in combination – together with the development 
of more effective methods for siRNA delivery in the coming years. The study of Cdc20 functions in the control of cell 
division has largely been focused on its interaction with the MCC and APC/C [50, 86–88]. By contrast, far less is known 
about the regulation of Cdc20 expression by upstream regulators, including p53 (which acts as a negative regulator, [89]); 
FOXM1 (a transcriptional activator), and possibly Emi1 and Usp44. It is encouraging that suppression of FOXM1 expression 
by shRNA decreased Cdc20 levels in glioblastoma, a prevalent and deadly type of brain tumour. While the APC/C cofactor 
Cdh1 has for some time been considered a suitable therapeutic target for the treatment of tumours caused by 
chromosome segregation defects, the potential therapeutic value of targeting Cdc20 (alone or in combination with other 
therapies) for the prevention of premature mitotic exit remains largely unexplored [65, 90]. 
Concluding Remarks 
The use of emerging technologies such as single-molecule methods and super-resolution microscopy in combination with 
traditional biochemical, cellular, and structural biology approaches has revealed new details of the remarkable roles of 
Cdc20 in APC/C regulation in health and disease. These advances have provided new molecular details of the role of Cdc20 
in the dynamics of SAC complex assembly and revealed Cdc20 to be a central organising centre for the accurate control of 
chromosome segregation and the timely end of mitosis. Future work should aim to unveil the functions of the different 
Cdc20 pools in the cell, provide a quantitative description of how changes in the concentration of the Cdc20 pools 
influence SAC signalling and mitotic exit in normal and tumour cells, and assess the therapeutic potential of targeting 
Cdc20 for the treatment of the diverse human cancers associated with chromosome segregation defects (see Outstanding 
Questions). 
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Trends 
 
Phosphorylation and dephosphorylation cascades acting on cell-division cycle protein 20 homologue (Cdc20) control cell 
division and genome stability. 
 
Various pools of Cdc20 complexes exist in the cell and undergo dynamic remodelling. 
 
Cdc20 is abnormally expressed in a wide range of tumours. 
 
Cdc20 constitutes a potential novel target for the treatment of cancer. 
 
The combination of traditional structural biology approaches with emerging technologies such as single-particle methods 
and high-resolution cryo-electron microscopy has enabled us to learn new details of Cdc20 functions in health and disease. 
These technological advances have facilitated a mechanistic understanding of Cdc20-dependent allosteric regulation of the 
anaphase-promoting complex or cyclosome (APC/C) at an unprecedented level of detail. 
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Glossary 
Aneuploidy: a prevalent form of genetic instability observed in many types of human cancer. Aneuploidy is a condition in 
which premature separation of sister chromatids results in the loss or gain of chromosomes in daughter cells. 
Chemical space: a key concept in drug discovery that refers to the ensemble of all possible chemical compounds adhering 
to a given set of construction principles and boundary conditions to be considered in the search for new drugs. 
Degron: a specific protein degradation signal that is required for the regulated destruction of the protein degradation rate. 
A degron can be a short amino acid sequence or a structural motif. Some central components of the SAC, including Cdc20, 
contain multiple degrons. 
Hop1p, Rev7p, and MAD2 (HORMA) domain: functions as an adaptor for the recruitment of other proteins. Proteins 
containing this domain are involved in SAC and meiotic checkpoint signalling and in the regulation of meiotic 
recombination. 
Kinetochore: from the Greek kinētikos, ‘of motion’, and chōros, ‘place’ refers to the site for attachment of chromosomes to 
the microtubule spindle fibers that pull sister chromatids apart during mitosis and meiosis. 
Single-particle analysis: a computerised image-processing technique where projection images of individual macromolecular 
complexes (a.k.a. particles) from cryo-EM samples are sorted to build a 3D reconstruction of the complexes, often with 
near-atomic resolution. 
Spindle assembly checkpoint (SAC): an evolutionarily conserved safety device of eukaryotic organisms that ensures the 
fidelity of chromosome segregation on cell division. During mitosis or meiosis, the SAC prevents anaphase onset until all 
chromosomes are properly attached to spindle microtubules. 
TNM staging system: the most widely used system to describe the stage of a cancer originating from a solid tumour. Most 
hospitals and medical centres use the TNM system as their main method for cancer reporting. ‘T’ refers to the size and 
extent of the main (usually referred to as the primary) tumour, ‘N’ to the number of nearby lymph nodes that have cancer, 
and ‘M’ to whether the cancer has metastasised (i.e., spread from the primary tumour to other parts of the body). 
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Box 1. Figure I. A Simplified View of Anaphase-Promoting Complex or Cyclosome (APC/C) Regulation by Cell-Division Cycle 
Protein 20 Homologue (Cdc20). (A) Cdc20 binds to APC/C and recruits APC/C substrates through interactions with short, 
linear amino acid sequences (degrons) present in the target proteins. (B) When forming part of the mitotic checkpoint 
complex (MCC), Cdc20 binds to APC/C–Cdc20 to form an APC/C–Cdc20–MCC assembly that adopts two main 
conformational states: open and closed. In the open conformational state, the APC/C–Cdc20–MCC assembly is not in close 
proximity to APC/C's catalytic core and the E2 coenzyme, which normally provides ubiquitin for transfer to target proteins. 
In the closed conformational state, Cdc20 bound to the MCC and budding uninhibited by benzimidazoles-related 1 (BubR1) 
define a continuous surface that interacts with Cdc20–APC/C [49,50] thus regulating allosterically the UBE2C-dependent 
ubiquitination of APC/C substrates. (C) Structure superposition of the APC/C–Cdh1 and APC/C–Cdc20 complexes reveals 
similar modes of binding of the two WD40 proteins to APC/C. 
 
15 
 
 
 
 
 
 
 
Figure 1. Domain Organisation of Cell-Division Cycle Protein 20 Homologue (Cdc20) and Core Spindle Assembly Checkpoint 
(SAC) Proteins. Cdc20 contains diverse motifs that mediate its multiple functions in the SAC including its binding to mitotic 
arrest deficient-like 2 (Mad2) and budding uninhibited by benzimidazoles (Bub)-related 1 (BubR1) and its phosphorylation 
by Bub1. Bub1 and BubR1 also contain diverse degrons. Mad2 is mainly organised in a Hop1p, Rev7p, and MAD2 (HORMA) 
domain. Bub3 shares a similar fold (WD40 repeat) with Cdc20. 
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Figure 2. Cell-Division Cycle Protein 20 Homologue (Cdc20) Forms Diverse Complexes. (A) Crystal structure of a Cdc20 
fragment lacking the N-terminal region revealed a WD40-repeat domain comprising a seven-bladed b-propeller topology 
(PDB 4GGD). (B) 3D crystal structure of the mitotic checkpoint complex (MCC) from fission yeast (PDB 4AEZ) comprising the 
proteins Cdc20, mitotic arrest deficient-like 2 (Mad2), and the N-terminal budding uninhibited by benzimidazoles- related 1 
(BubR1) (Mad3 in yeast). (C) Cryoelectron microscopy (cryo-EM) structure model of anaphase promoting complex or 
cyclosome (APC/C)–Cdc20–MCC. Because phase information is preserved in cryo-EM images as opposed to X-ray 
crystallographic reflections, cryo-EM maps can provide more structural details of large and rigid complexes than X-ray 
electron-density maps at the same nominal resolution [91]. 
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Figure 3. Cell-Division Cycle Protein 20 Homologue (Cdc20) Inhibitors. Chemical structures of the small-sized inhibitors of 
Cdc20 reported to date. The compounds belong to different chemical families suggesting that an ample chemical space can 
be exploited for the design of new inhibitors of higher potency and/or specificity. 
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Table 1. Small-Sized Inhibitors of APC/C–Cdc20 Functions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound  
name 
 
Mode  
of action 
 
Reference 
 
Apcin 
Competes with the D-box-binding pocket thus obstructing 
APC/C substrate loading. 
[66] 
BCHHD 7c 
Suppressor of Cdc20 expression in pancreatic cancer cells 
resistant to chemiotherapy. 
[76] 
CFM-4 
 
Down-regulation of Cdc20 expression in breast cancer 
cells. 
[75] 
Genistein Down-regulation of Cdc20 in diverse human tumours. [72, 73] 
Ganodermanontriol 
and Mycophyto 
complex 
Down-regulation of Cdc20 expression; inhibition of cell 
proliferation and invasion in breast tumours. 
[69, 71]  
NAHA 
Down-regulation of Cdc20 in breast cancer cells, 
negatively affecting cell proliferation and colony 
formation. 
[68] 
Pro-TAME 
Disruption of the APC/C-Cdc20 interaction leading to 
lower APC/C activity upon substrates. 
[81] 
TAME 
Impairing of Cdc20 recruitment to the APC/C thus 
inhibiting APC/C activity. 
[82] 
Taxol and 
Nocodazole 
Affects Mad2-dependant suppression of APC/C-Cdc20  
Withaferin A 
Enhanced  Cdc20 degradation, causing 
mitotic delay.  
[83] 
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Outstanding Questions 
How do Cdc20 complexes link the SAC to other signalling networks in a cell and what are the physiological implications of 
such molecular interactions? 
 
What is the role of Cdc20 in the assembly/disassembly of the APC/C in time and space? 
 
How do phosphorylation and dephosphorylation cascades acting on Cdc20 affect cell division and genome stability? 
 
How exactly do the various subcellular pools of Cdc20 ensure proper chromosome segregation? 
 
Can the APC/C subunits play different roles independent of the APC/C holoenzyme? 
 
 
 
 
 
 
 
 
 
